REGOLIEVA 40MG

Regorafenib Tablet BP 40mg

REGOLIEVA 40 MG (Regorafenib Tablets BP 40 mg) is a prescription anticancer medicine containing Regorafenib 40 mg, an oral multi-kinase inhibitor used in the treatment of certain advanced cancers. Regorafenib belongs to a class of medicines known as Targeted Therapy Agents, which work by blocking multiple protein kinases involved in tumor growth, cancer progression, and blood vessel formation. Regorafenib inhibits various signaling pathways responsible for cancer cell proliferation and angiogenesis (formation of new blood vessels that supply tumors). By targeting these pathways, the medicine helps slow tumor growth and disease progression. REGOLIEVA 40 MG is commonly prescribed for the treatment of metastatic colorectal cancer (mCRC), gastrointestinal stromal tumors (GIST) after failure of prior therapies, and hepatocellular carcinoma (HCC) in selected patients. It may also be used according to the oncologist's recommendation as part of specific cancer treatment protocols. The medicine is administered orally and should be taken exactly as prescribed by a qualified healthcare professional experienced in oncology treatment. REGOLIEVA 40 MG is commonly used for: Metastatic Colorectal Cancer (mCRC) Gastrointestinal Stromal Tumor (GIST) Hepatocellular Carcinoma (HCC) Advanced Solid Tumors Targeted Cancer Therapy Oncology Treatment Programs Tumor Growth Control Cancer Progression Management Manufactured according to stringent pharmaceutical quality standards, REGOLIEVA 40 MG is designed to provide consistent quality, safety, and therapeutic effectiveness. Patients receiving Regorafenib therapy require regular monitoring of liver function, blood pressure, and overall health status throughout treatment. Due to its targeted mechanism of action and proven clinical efficacy, REGOLIEVA 40 MG remains an important option in modern oncology care.